Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04843449
- Locations
- 🇨🇳
Hunan provincial people's hospital, Changsha, Hunan, China
A Study of the Pharmacokinetics of ASC09F in Healthy Subjects
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04547894
- Locations
- 🇨🇳
Beijing Youan Hospital, Capital Medical University, Beijing, Beijing, China
A Study of the Relative Bioavailability of ASC41 in Healthy Subjects
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04527250
- Locations
- 🇨🇳
Hunan provincial people's hospital, Changsha, Hunan, China
A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 207
- Registration Number
- NCT04465890
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04358523
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT04352361
- Locations
- 🇨🇳
Hunan provincial people's hospital, Changsha, Hunan, China
A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03430830
- Locations
- 🇨🇳
First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 425
- Registration Number
- NCT03362814
- Locations
- 🇨🇳
Peking University People's hospital, Beijing, Beijing, China
Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03288636
- Locations
- 🇨🇳
The first hospital of Zhejiang province, Hangzhou, Zhejiang, China
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 141
- Registration Number
- NCT03020082
© Copyright 2024. All Rights Reserved by MedPath